Skip to main content

Conclusions

Buy Article:

$32.00 plus tax (Refund Policy)

Abstract:

The OECD project on pharmaceutical pricing policy has taken a close look at the evolving market for pharmaceutical products and the ways in which pricing policies serve to shape that market, yielding a number of conclusions. As tools for meeting a range of pharmaceutical policy objectives, the approaches most widely used in OECD countries to arrive at prices for pharmaceuticals ‐ external and internal price referencing ‐ are problematic in a number of respects. International price benchmarking (or external referencing) is readily gameable by the pharmaceutical industry and ‐ by reducing firms' willingness to price to market ‐ contributes to access and affordability problems in the lower‐income OECD countries, some of which spend close to a third of their health‐care resources on pharmaceuticals.

Document Type: Review Article

Publication date: September 1, 2008

oecd/16080289/2008/00002008/00000006/8108041ec008
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more